Gain Therapeutics, Inc. (GANX)
GANXNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$1.11
-0.0490 (-4.23%) today
Pre-market, Nov 11, 4:00 PM ET
- Market cap
- $48.44m
- P/E
- –
- EPS, last 4 quarters
- $-0.4200
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.9402 to $4.34
- Average volume
- –
- Previous close
- $1.16
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $7.20, +548.6% from here
Earnings
next estimate $-0.1300Next report
Dec 2025
+21.4%
Mar 2026
0.0%
Jun 2026
+21.4%
Sep 2026
+46.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.79m | -$4.47m | -$5.35m | -$4.68m |
| Net income | -$5.28m | -$4.54m | -$5.61m | -$4.68m |
News
8 latest- Gain Therapeutics Q3 Loss Narrows RTTNews · 1 day ago
- Gain Therapeutics, Inc. Appoints Jeanette Weidner as Vice President, Finance, Effective October 28, 2026Fintel · Oct 29, 2026
- Gain Posts Narrower Loss In Q2; Phase 1b Data For Rexaceract Due In Q4 2026 RTTNews · Aug 17, 2026
- Gain Updates Parkinson's Pipeline, Promotes Executives; Cash Runway Into Q2 2027 RTTNews · Jul 17, 2026
- After Hours Most Active for Jun 29, 2026 : CAG, NVDA, GANX, INN, AAPL, ARI, ANNX, RKT, CSCO, CMG, ACN, HTZNASDAQ.com · Jun 29, 2026
- Gain To Present New Parkinson's Disease Data On GT-02287 At International GBA1 Meeting; Stock Up RTTNews · Apr 24, 2026
- Gain Therapeutics (GANX) Price Target Increased by 11.76% to 7.75Fintel · Dec 20, 2025
- HC Wainwright & Co. Reiterates Gain Therapeutics (GANX) Buy RecommendationFintel · Dec 19, 2025
The company
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate, rexaceract is currently being evaluated for the treatment of PD with or without a GBA1 mutation in a Phase 1b clinical trial. The Company believes rexaceract has further potential in Gaucher's disease, dementia with Lewy bodies, and Alzheimer's disease. Gain has multiple undisclosed preclinical assets targeting lysosomal storage disorders, metabolic diseases, and solid tumors. Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- gaintherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.